Upexi enters its May 15 earnings print carrying one of the more combustible short setups in the small-cap universe — 27% of the free float sold short, a borrow availability rate of just 27%, and a cost to borrow running near 18% annualised — all while the stock dropped 8% in a single session on Tuesday to close at $1.35.
Short sellers have been aggressive, but the intensity is easing at the margin. Short interest peaked above 22 million shares in early April, when borrow costs were north of 30% and availability had been fully exhausted for weeks on end. Since then, roughly 5.8 million shares of short interest have been covered — a 26% reduction over the past month — and borrowing costs have retreated to the high-teens. Availability has loosened from near-zero to 27%, though that remains tight by any standard: fewer than one share is available to borrow for every three already out on loan. The ORTEX short score of 77.9 still ranks the stock in the 3rd percentile of its universe on short positioning, a signal that the bears have not walked away.
The options market tells a very different story. The put/call ratio is running at just 0.08 — extraordinarily call-heavy — and has barely moved over the past month. That skew reflects the stock's identity: UPXI is less a personal care company and more a Solana proxy, having pivoted to accumulate and stake SOL as its central treasury strategy. Call buyers are wagering on a SOL recovery; short sellers are betting the crypto-correlated business model is structurally fragile. The bear case centres on heavy reliance on SOL price appreciation, regulatory risk to the Solana ecosystem, and a debt-funded acquisition strategy that leaves little margin for error if token prices stay soft. The bull case holds that the stock remains deeply undervalued relative to its SOL holdings and that staking yield provides a durable revenue stream if the token stabilises.
The sole analyst covering the stock — Cantor Fitzgerald's Brett Knoblauch, maintaining an Overweight — cut his target from $6 to $2 in February after the previous print triggered a two-day loss of more than 22% and a five-day drawdown exceeding 31%. That reaction data is the most relevant context heading into Thursday: the last two earnings events both produced sharp, multi-day sell-offs, and short interest was notably higher through each of those episodes than it is today. The May 15 report is therefore a test of whether the covered shorts were right to reduce exposure, or whether the remaining 27% of the float still on loan proves prescient as the company discloses the impact of SOL's recent volatility on its staking revenue and balance sheet.
See the live data behind this article on ORTEX.
Open UPXI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
